September 1, 2021
September 1, 2021 – The U.S. FDA is requiring new and updated warnings on a class of drugs called JAK inhibitors due to an increased risk of cancer
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
August 31, 2021
August 31, 2021 – Keytruda® (pembrolizumab) has been U.S. FDA approved as a first-line treatment for locally advanced or metastatic urothelial carcinoma (UC)
August 30, 2021
August 30, 2021 – Due to an expanded indication granted by the U.S. FDA, Briviact® (brivaracetam) tablets, oral solution, and injection for intravenous (IV) use are now approved
August 27, 2021
August 27, 2021 – Drug manufacturer Roche is withdrawing a Tecentriq® (atezolizumab) metastatic triple
negative breast cancer (mTNBC) indication following consultation
August 27, 2021
August 27, 2021 – Teligent Pharma is recalling one lot of Lidocaine HCl Topical Solution 4%, 50mL, packaged in a screw cap glass bottle. This recall extends
August 27, 2021
August 27, 2021 - The Assistant Secretary for Preparedness and Response (ASPR) and the U.S. FDA have announced updates to emergency use authorization
August 25, 2021
August 25, 2021 – The U.S. FDA has approved Skytrofa® (lonapegsomatropin-tcgd) to treat pediatric patients who are at least one year old, weigh at least 11.5kg
August 25, 2021
August 25, 2021 – The U.S. FDA has granted a new indication to Tibsovo® (ivosidenib tablets) for use in
adults who have previously treated